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Abstract: We report the syntheses of antifungals containing the novel pharmacophores: 
oxaziridines, sulfonyloxaziridines, nitrones and nitronyl nitroxides. We hypothesized that 
multiple copies of the pharmacophore per molecule might be a prerequisite to enhance 
efficacy against the opportunistic pathogen, Pneumocystis carinii. Therefore structural 
optimization of the leads was based on this new “multivalency” approach. All 
bisoxaziridines were inactive, but a trisoxaziridine caused ca. 50% reduction of the number 
of P. carinii tropozoites, compared to TMP-SMX, and a hexaoxaziridine at 1 µg/ml showed 
activity comparable to the currently used drug, TMP-SMX. Insertion of three units of the 
nitronyl nitroxide pharmacophore per molecule afforded an antifungal triradical with 
activity comparable to TMP-SMX at 1 µg/ml; at 25 µg/ml and at 10 µg/ml the triradical was 
better. The results lend further support to the oxidoredox pharmacophore hypothesis, and the 
enhancement of activities observed demonstrates the high potential and benefits of applying 
the concept of multivalency to drug development. 
Keywords: AIDS, opportunistic infections, Pneumocystis carinii, multivalency in drug 
design, antifungals, oxaziridines, sulfonyloxaziridines, nitrones, nitronyl nitroxides. 
 
Introduction 
Human immunodeficiency virus (HIV) infection, with its clinical progression to AIDS, has become 
one of the leading causes of death in the world and the number one cause in Africa [1]. According to 
the World Health Organization, at least 42 million people are HIV-infected worldwide.  The complex 




regimen of antiretroviral drugs that HIV-positive patients take to control the virus has been credited 
with the notable reduction in AIDS morbidity and mortality seen in the United States and other 
affluent nations, but in the developing world, where 90% of the HIV-infected people live, adequate 
means are not available for treatment with highly active antiretroviral therapy (HAART) [2].  
Moreover, these therapies fail in up to 40% of HAART patients because of the complexity and toxicity 
of the drug regimens, and when HAART is stopped, the virus rapidly rebounds. Significantly, viral 
resistance [3] is beginning to counter the success of HAART, and a model based on the rate of increase 
of drug-resistant HIV infections in San Francisco predicts that by 2005, 42% of the city’s cases will be 
resistant [4]. A new opportunity for long-term control of HIV materialized with the recent discovery of 
chemokine receptors that play an essential role in HIV infection [5-6]. In addition to the CD4 receptor, 
the chemokine receptors CCR5 and CXCR4 are required to mediate viral entry into macrophages and 
T cell hosts. Therefore, these receptors provided alternate and attractive new targets for drug 
development. Since the discovery that in the early stages of HIV infection macrophage-tropic viruses 
that use the CCR5 receptor predominate, and that people with mutant copies of the gene coding for 
CCR5 are highly resistant to HIV infection, intensive efforts to discover CCR5 antagonists led to 
several leads. Among the promising nonpeptidic agents are the quaternary ammonium anilide (TAK-
779) from Takeda Chemical Industries [7], the bipiperidine N-oxide (SCH 351125) from Schering-
Plough [8], the CCR5 antagonists from Merck [9], and the macrocyclic chemokine mimics we 
developed [10]. It is expected that viral entry inhibitors soon will be available to relieve the severe 
problems associated with the long term use of drug cocktails administered in HAART.  However, new 
drugs that block the chemokine receptors, CXCR4 and/or CCR5 may not be without problems [11]. 
Thus, knocking out the gene for SDF-1, the chemokine that naturally binds to CXCR4, caused 
developmental problems in mice. Because people without CCR5 are healthy, a better approach would 
be to use a CCR5-specific drug delivered in the early stages of the infection while the virus is M-tropic 
to prevent it from turning T-tropic. However, the possibility that blocking the CCR5 receptor would 
force the virus to mutate to the T-tropic strain, or would induce the virus to switch to other coreceptors 
to gain entry into cells cannot be excluded. 
While better therapies to prevent HIV infection or to eradicate the virus from cells are desperately 
needed, there is an even more pressing need to combat the opportunistic infections (OIs) that 
eventually take the life of AIDS patients. Among OIs associated with AIDS, Pneumocystis carinii 
pneumonia (PCP) affects >70% of AIDS patients, and is one of the most devastating complications of 
the immunosuppression associated with the disease [12]. Cryptococcus neoformans causes potentially 
fatal meningitis in 7-10% of AIDS patients and Candida albicans causes oral and esophageal 
candidiasis in >70% of them. Several other infective agents such as Cryptosporidium parvum, 
Histoplasma capsulatum, Toxoplasma gondii, Mycobacterium avium, and Mycobacterium tuberculosis 
cause debilitating diseases in AIDS patients [13]. However, PCP remains the main cause of mortality 
despite available prophylactic and therapeutic regimens. One of the most effective drug regimens 




currently used against mild to moderate PCP is a combination of trimethoprim-sulfamethoxazole 
(TMP-SMX) [14]. However, this combination of a sulfa drug with a dihydrofolate reductase inhibitor 
has more adverse effects on AIDS patients than on non-immunocompromised subjects. For those 
patients who cannot tolerate TMP-SMX, the drug of choice is MEPRON (Atovaquone), an 
antiprotozoal naphthalenedione derivative [14]. However, the success rate for both drugs is low, 62% 
and 64% respectively. For patients for whom these drugs fail, and are switched to the alternate drug 
pentamidine, the prognosis is poor with high mortality rates. When pentamidine, which binds within 
the AT-rich regions of DNA [15] was administered to AIDS patients, 57.5% developed some adverse 
reaction, 8.7% life-threatening. The fungistatic effect of macrophages on Cryptococcus neoformans is 
lacking in immunocompromised patients causing potentially fatal meningitis. It is suppressed with 
Fluconazole after primary treatment with Amphotericin B (preferably with flucytosine). About 50% of 
the AIDS patients do not survive treatment with flucytosine, and mortality during the course of therapy 
is 33% and 40% for Amphotericin B and Fluconazol, respectively. Amphotericin B, a long, rigid 
polyene macrolide traverses the fungal cell wall and causes plasma membrane damage. It is extremely 
toxic to the kidneys. The available treatments for OIs listed above indicate that TMP-SMX and 
MEPRON do not work for about 40% of AIDS patients, and Fluconazole does not solve the problem 
of cryptococcal meningitis; Amphotericin B is so toxic and difficult to tolerate that it earned the 
nickname of "Amphoterrible". Clearly, there is an urgent need to develop better drugs conducive to 
safer and more effective therapies. 
We started development of antifungals against P. carinii based on the hypothesis that compounds 
with oxidoredox properties can damage many pathogens which cause OIs. Subsequently, novel 
oxidoredox pharmacophores [16], oxaziridines, sulfonyloxaziridines, nitrones, and nitronylnitroxides 
synthesized in our laboratory were inserted into carrier structures to yield active leads against P. 
carinii. Importantly, we hypothesized that multiple copies of the pharmacophore per molecule might 
be necessary to achieve high in vivo efficacy [17]. Therefore structural optimization of the leads was 
initiated based on this new “multivalency” approach. Multivalency is the simultaneous attachment of 
two or more binding sites on one biological molecule or organism (such as protein or virus) to multiple 
receptor sites on another (such as a cell surface). Multivalent interactions are ubiquitous in biological 
systems where thousand- and million-fold increases in binding affinities were observed when divalent 
and trivalent ligands replaced monovalent ones [18]. However, only very recently has the high 
potential of multivalency in drug design been fully recognized [19]. In our optimization studies using 
multivalency, the difficulties of employing novel pharmacophores and of attaching multiple copies of 
them to appropriate scaffolds have now been overcome with the syntheses of highly active compounds 
effective against P. carinii. The aim of this paper is to report the syntheses of novel oxaziridines, 
sulfonyloxaziridines, nitrones and nitronyl nitroxides, and to demonstrate the potential of multivalency 
through the enhanced biological activities of these compounds. 
 




Results and Discussion 
The oxidoredox hypothesis we proposed recently to account for the mode of action of the antifungal 
oxaziridines, sulfonyloxaziridines, nitrones and nitronyl nitroxides is detailed in reference [16] and is 
summarized below.  
Activated macrophages produce a cytotoxic flux that kills microorganisms. This flux consists of 
high, local, and contemporaneous concentrations of superoxide anion radical O2-•, nitric oxide, •NO, 
and the reaction product of these two, peroxynitrite, HNOO-. Nitric oxide is produced by the 
endotoxin and cytokine-inducible nitric oxide synthases (iNOS), that catalyze the conversion of L-
arginine to L-citrulline and •NO, at the expense of NADPH and O2 [20]. Nitric oxide and related 
reactive nitrogen intermediates are being increasingly recognized to have microbicidal activities 
against a wide spectrum of pathogens, including fungi [21-22] and protozoa [23]. Of particular interest 
for OIs is the inhibition of Cryptococcus neoformans replication by nitrogen oxides that supports the 
role of these molecules as effectors of macrophage-mediated cytostasis [22]. Activated human 
neutrophils exert microbicidal activity through two types of mechanisms: one in which the intact 
neutrophils' H2O2-myeloperoxidase-Cl- system mediates the production of HOCl, which in turn 
chlorinates endogenous amines to yield a new group of powerful oxidizing agents, chloramines,  and 
the other in which granule-poor cytoplasts have a •NO-dependent cytotoxic mechanism [24]. Of 
further interest is how Rac1 and Rac2, the small GTP-dependent factors, activated upon exposure to 
microorganisms, regulate O2-• generation in both macrophages and neutrophils [25]. According to the 
oxidoredox hypothesis [16], multivalent drugs containing oxidoredox pharmacophores could mimic 
the action of macrophage and neutrophil oxidants or could interact with macrophage/neutrophil-
derived oxidants in specific ways to modulate the physiological concentrations of the latter. To attempt 
modulation of microbicidal activity, four different functionalities, each with oxidoredox properties, 
were studied as potential pharmacophores against OIs: oxaziridines that are extensively employed in 
organic synthesis as oxygen transfer agents, sulfonyloxaziridines that are among the most effective 
oxidizing agents currently available for chiral epoxidations, nitrones that are well known spin traps and 
yield oxaziridines by electrocyclic ring closure, and nitronyl nitroxides that can be derived from 
nitrones by spin trapping and which are also the putative in vivo intermediates [16] derivable from 
nitrones by a reductive or an oxidative pathway. The structures of the oxidoredox pharmacophores 


















Synthesis and biological activity of compounds with multiple copies of the oxaziridine 
pharmacophore. 
To evaluate the potential of oxaziridines as antifungals, it was necessary to determine how many 
oxaziridine pharmacophore units a molecule must contain to achieve optimal antifungal activity. 
However, only a few compounds are known to contain more than one oxaziridine unit, and, except for 
the macrobicyclic hexaoxaziridine [17] synthesized by us, none are known to contain more than two. 
Therefore, a systematic investigation to synthesize compounds with multiple oxaziridine 
pharmacophore units, such as bis-, tris-, and hexaoxaziridines was undertaken as described below. 
 
Bisoxaziridines: 
The few known bisoxaziridines were not deemed suitable for our studies, either because of their 
lack of stability and/or because of the limited possibilities for appropriate functionalization to enhance 
pharmacological properties. We selected for synthesis target structures that contain N-alkyl, N-
cycloalkyl, and N-aryl substituents on the oxaziridine ring (Table 1). In some of the target structures an 
electron withdrawing group is attached to the oxaziridine nitrogen to enhance thermal stability and to 
avoid rearrangements. Unlike known oxaziridines, where stabilization was sought but was not always 
achieved by an inert N-tert-butyl substituent, in the target compounds a hydroxymethyl group attached 
to the quaternary carbon was used instead (Table 1, entries 1-3). The quaternary carbon was expected 
to enhance stability by blocking rearrangements, and the hydroxymethyl group should increase water 
solubility and provide a functionalization site for modulation of biological activity. Condensation of 
aldehydes with diamines, or of amines with dialdehydes afforded bisimine precursors which were then 
oxidized to yield the target bisoxaziridines (Scheme 1). 
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Scheme 1. Bisaldimine precursors and target bisoxaziridines. 
 
Except for entry 16, all bisaldimine intermediates were obtained in good yields by condensations of 
the amines and aldehydes in anhydrous methanol or acetonitrile either at room temperature or at reflux 
for 30 minutes (Table 1). The structures of the bisaldimines were confirmed by their chemical 
ionization mass spectra (CI-MS), 1H and 13C  nmr spectra. All the bisaldimines, except the 
bisdiphenylphosphinoyl imine (entry 16, doublet at 9.35 ppm), had the characteristic signal of the 
imino protons between 8-9 ppm. To oxidize the bisaldimines to the target bisoxaziridines, three 
oxidants,   meta-chloroperbenzoic   acid  (m-CPBA),  potassium  peroxymonosulfate  (Oxone) buffered  























































































































































































































with KHCO3, and dioxirane were employed. Despite varying the reaction conditions for each oxidant, 
only three of the target bisoxaziridines could be prepared in this manner; 1, 2, and 3 (entries 1, 4, and 
16, Table 1).  However, these three bisoxaziridines were obtained in good to excellent yields by m-
CPBA oxidation of the precursor bisimines. The failure to isolate bisoxaziridines (entries 2-3, and 5-
15) cannot be attributed entirely to the failure of the oxidizing agents employed. More likely, the 




bisoxaziridines’ low stability and propensity to fragment into two or more products is a contributing 
factor. The stabilizing effect of an N-tert-butyl substituent is well-documented; nevertheless, even 
some of the N-tert-butyl substituted oxaziridines are known to decompose spontaneously at room 
temperature [26]. It was reported that oxaziridines having an N-methylene or an N-methinyl 
substituent are prone to spontaneous decomposition, decomposition by acids, and by bases to yield 
aldehydes, ketones, and ammonia. Nevertheless, an N-methinyl substituted bisoxaziridine, 2, (entry 4, 
Table 1) was stable, and could be obtained in 52% yield by m-CPBA oxidation of its bisaldimine 
precursor. The 1H nmr spectrum in CDCl3 of bisoxaziridine 2 showed a characteristic peak for the 
oxaziridine protons at 4.49 ppm. Proton chemical shifts are known to depend on the orientation of 
adjacent lone pairs of electrons, with protons trans to the lone pairs resonating at higher field than 
those cis. Several explanations for the phenomenon have been offered, such as upfield shifts caused by 
transfer of electron density via the back lobe of the nitrogen lone pair, or by steric factors present when 
a nitrogen substituent is cis to the protons of interest.  Alternatively, it has been suggested that the 
anisotropic character of the nitrogen lone pair causes the protons cis to it to shift downfield. Boyd et al. 
[27] reported that in oxaziridines, protons cis to the lone pair resonate at ca. 5.4 ppm, whereas protons 
trans to it resonate close to 4.7 ppm (Figure 1). Since the oxaziridine protons in N-methinyl substituted 
bisoxaziridine  2  resonate at 4.49 ppm,  trans   configuration  can be assigned to this bisoxaziridine.  
13C Nmr is another diagnostic tool to assign cis versus trans configuration to oxaziridines [28]. 
Oxaziridine carbons resonate in the narrow range of 79-84 ppm. Aliphatic carbons trans to the 
nitrogen lone pair in oxaziridines experience a considerable upfield shift relative to cis substituents 
(Figure 2). Moreover, although smaller than the 9 ppm upfield shifts observed for aliphatic carbons, 
upfield shifts of 3.5 ppm are characteristic of ipso carbons trans to the nitrogen lone pairs. In 
agreement with the trans  geometry assigned to 2, the oxaziridine carbon resonates at 79.0 ppm, and 
the ipso carbon’s signal is at 129.2 ppm (Figure 2). Furthermore, the signals of the oxaziridine protons 
and carbons both appear as singlets in the 1H and 13C nmr spectra indicating that the two oxaziridine 









H cis: ~ 5.4 ppmtrans: ~ 4 .7 ppm
 






















23.1 ppm 14.4 ppm
132.1 ppm 135.5 ppm
79.7 ppm 81.6 ppm
 
Figure 2. Lone pair effects on carbon-13 resonances in oxaziridines [28]. 




Like other active oxygen compounds, bisoxaziridine 2 (Figure 3) transfers its oxygen atoms to 
triphenylphosphine quantitatively. Thus, addition of Ph3P to a CDCl3 solution of 2 led to loss of the 
oxaziridine proton’s signal at 4.49 ppm with concomitant appearance of the imine signal at 8.2 ppm. 
Mass spectroscopy is especially useful for characterizing oxaziridines because they lose oxygen from 
their molecular ions. The CI-mass spectrum (NH3 gas) of bisoxaziridine 2 showed the successive loss 
of two oxygen atoms, yielding fragments at m/z  439 and 423, corresponding to 16 mass unit losses 
from the [M+1]+ ion. When the bisoxaziridine 2, homogeneous by tlc, was submitted to hplc analysis, 
two well separated peaks were observed. The separated peaks had identical mass spectra, and when the 
separated peaks of 2 were reinjected for hplc analysis, single peaks were observed. This, and the 
spectral analyses suggested that 2 is a diastereomeric mixture. Since the diastereomeric mixture was 
devoid of antifungal activity, preparative hplc separation of the diastereomers was not pursued. 
Bisoxaziridine 1 (Figure 3) was synthesized by condensation of 2-amino-2-methyl-1-propanol with 
terephthaldicarboxaldehyde, followed by oxidation of the bisimine with m-CPBA. Reaction with PPh3, 
and the mass spectrum of 1 confirmed the presence of two atoms of active oxygen per molecule. The 
1H nmr spectrum of 1 showed a singlet for the oxaziridine signal at 4.78 ppm, and the 13C nmr 
spectrum showed the oxaziridine carbon resonance at 73.3 ppm, establishing the trans geometry of the 
oxaziridine moieties. The bisoxaziridine 3 (Figure 3) was prepared by Arbuzov type PIII - PV 
rearrangement of the O-diphenylphosphino-oximes to the bis-diphenylphosphinoyl imines, and 
subsequent biphasic oxidation of the imines with m-CPBA according to Scheme 2. Apart from the 
popular sulfonyloxaziridines, few other types of N-functionalized oxaziridines are known. Until now, 
N-phosphinoyloxaziridines were limited to monofunctionalized derivatives, and so the bis-diphenyl 
phosphinoyloxaziridine 3 is the first member of a hitherto unknown class of oxaziridines bearing two 
oxaziridinyl moieties. The structures of the intermediates, and that of 3, were ascertained by their 1H, 
13C nmr, and CI-MS spectra, and by the transfer of the two active oxygens of 3 to PPh3. The CI-MS 
spectrum of 3, characteristic of oxaziridines, showed sequential loss of two 16 mass units from the 

























Figure 3. Structures of the bisoxaziridines 1, 2, and 3. 

































Scheme 2. Synthesis of bisdiphenylphosphinoyloxaziridine, 3. 
 
 
included the precursor bisimine proton resonance, a doublet at 9.35 ppm, deshielded by the proximity  
of the diphenylphosphinoyl groups cis to them, and characterized by a coupling constant of 3JPH=31.5 
Hz, indicating that the geometry of both imines was trans. The signal of the two oxaziridine protons 
(cis to the phosphinoyl moieties), a doublet at 5.65 ppm with a coupling constant of 3JPH=8 Hz, 
confirmed the trans geometry of the oxaziridine groups. 
The bisoxaziridines showed no antifungal activity against Pneumocystis carinii at concentrations 
low enough to predict in vivo potential. Therefore, to establish the minimum number of oxaziridine 
pharmacophore units per molecule that are a prerequisite for antifungal activity, synthesis of 
oxaziridines containing three pharmacophore units per molecule was undertaken next. 
 
Trisoxaziridines: 
Since the average molecular weight of most of the useful small molecule drugs is below 1,000, and 
optimally falls in the range of 500-600 [29], to append several pharmacophore units to a molecule, 
macrocycles and dendrimers were envisaged as suitable carrier structures. Dendrimers are particularly 
attractive when the goal is to append identical functionalities (Figure 4). Here, this strategy is 
employed to append three oxaziridine pharmacophore units to the dendrimeric core, 2,4,6-tris(p-
formylphenoxy)-1,3,5-triazine, to obtain the trisoxaziridine 4. To the best of our knowledge compound 
4 is the first example of a trisoxaziridine. The 1,3,5-triazine was chosen as the central core of the 
dendrimer both to facilitate synthesis and to enhance the molecule’s drug potential. 1,3,5-Triazines are 
not toxic, and some triazine derivatives by themselves display fungicidal or antibacterial properties. 
Trisoxaziridine 4 was synthesized efficiently, in three steps according to Scheme 3. Reaction of p-
hydroxybenzaldehyde with cyanuric chloride gave 2,4,6-tris(p-formylphenoxy)-1,3,5-triazine in 78% 
yield. This trialdehyde was then condensed with 2-amino-2-methyl-1-propanol to yield the trisimine in 
95% yield. Oxidation of the trisimine  with m-CPBA in chloroform at room temperature afforded 4 in 
91% yield. This trisoxaziridine, a white powder, can be stored without decomposition at -20oC for 
several months. The presence of three active oxygens in 4 was corroborated by quantitative transfer of 
the oxygen atoms to PPh3. 
 
























































Scheme 3. Synthesis of the trisoxaziridine 4. 
 
 
The structures of trisimine and that of trisoxaziridine 4 were assigned on the basis of 1H, 13C nmr, 
FT-IR, and MS data. In the 1H nmr spectrum of trisoxaziridine 4 the signal of the three oxaziridine 
protons appears as a singlet at 5.03 ppm indicating that the three oxaziridines in 4 have identical, trans 
geometry. The 13C nmr shows a typical oxaziridine carbon resonance at 66.9 ppm. Unlike the 
trisimine, where the methyl signals have identical chemical shifts, the signals of the methyl carbons 
adjacent to the chiral nitrogen atom in the trisoxaziridine 4 appear as separate peaks at 14.2 and 18.5 
ppm. The FAB mass spectrum of 4 showed the typical fragmentation pattern of oxaziridines, along 
with fragmentation validating the particular substitution pattern present in 4. Thus, the fragments at 
m/z=687 [MH-16]+, 671 [MH-32]+, and 655 [MH-48]+ correspond to sequential loss of one, two, and 
three oxygen atoms from the 703 [M+1]+ ion.  
Unlike bisoxaziridines 1-3 that were inactive, trisoxaziridine 4 was active against P. carinii  at a 
concentration of 25 µg/ml. Over a period of seven days of incubation with P. carinii cultures, 4 caused 
ca. 50% reduction of the number of tropozoites compared to the control (Figure 5). This demonstrated 
that the number of oxaziridine pharmacophore units per molecule is a critical factor for modulation of 
antifungal activity. Therefore, to enhance the level of activity so that complete inhibition of P. carinii 
reproduction is achieved at concentrations of less than 10 µg/ml, synthesis of drug candidates 
containing six oxaziridine pharmacophore units per molecule was undertaken. 
 











The macrobicyclic hexaoxaziridine, 5 (Figure 6), the first macrocycle containing oxaziridine 
moieties, was highly active against Pneumocystis carinii in cultures at concentrations of <1 µg/ml [16]. 
This enhancement of activity demonstrated the high potential and benefits of applying the concept of 
multivalency to drug development. These antifungal studies were conducted by Professor Marilyn S. 
Bartlett’ s group at the Indiana University Medical School. The rat P. carinii cultivation method 
established at Indiana University using specific cell lines, careful standardization of inocula, and 
organisms from animals that have had the same strain passed over time has been used successfully to 
screen compounds and select those most likely to be effective in vivo. This culture method predicted 
the efficacy in animals of atovaquone, trimetrexate, albendazol, and 8-aminoquinolines [30]. The high 
level of in vitro activity against P. Carinii warranted in vivo testing of the compound requiring gram 
amounts of the material. However, due to the low yield of ca. 10% in the first synthesis of 5 [17], the 
compound was available only in milligram amounts. The second, improved synthesis (40% yield) 
together with the extensive structural studies that established the configuration of all the 12 
stereocenters in 5 will be published shortly. This improved synthesis yielded adequate amounts of 5 for 
in vivo studies. However, the very low solubility of 5 in water prevented its intraperitoneal delivery to 
mice, and when it was given orally, mixed with peanut butter, its rapid decomposition rendered it 
useless. Synthesis of a water soluble analog of 5 in which the six highly active oxaziridine moieties are 
carried by a dendrimer scaffold are in progress. 





Figure 6. Structure of hexaoxaziridine 5 (Macromodel) showing the two enantiomeric sets of (R,R) 
and (S,S) oxaziridines. 
 
 
Synthesis and antifungal activity of compounds with multiple copies of the sulfonyloxaziridine 
pharmacophore 
N-sulfonyloxaziridines are generally not only more stable than oxaziridines, but they are also more 
powerful oxidizing agents due to the enhanced electrophilicity of their oxygen atoms. The 
bissulfonyloxaziridine 6 with two sulfonyloxaziridine moieties, was obtained in 92% yield by m-
CPBA oxidation of the corresponding sulfonimine in presence of a phase transfer catalyst 
butyltriethylammonium chloride (BTEAC) (Scheme 4). The two oxaziridine moieties in 6 have 
identical geometry, as ascertained by spectral data. In vitro, 6 was active against P. carinii, at a 
concentration of 2.1 µM, comparable to that of pentamidine. In vivo testing in mice at the NIAID 
contractor's laboratory indicates it has no gross toxicity at 50 mg/kg/day, ip [16]. To ascertain whether 
increased multivalency will further enhance the antifungal activity, synthesis of a macrocyclic analog 
























a: Amberlyst 15/toluene, reflux, 16 h; 47%
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Scheme 4. Synthesis of bissulfonyloxazirine, 6. 




Synthesis and antifungal activity of compounds with multiple copies of the nitrone  and nitronyl 
nitroxide pharmacophores 
We have previously reported the synthesis and antifungal activity of compound VBN-3, a 
bisnitrone, that was highly active against P. carinii, both in vitro and in vivo [16]. Considering the 
several mechanisms by which VBN-3 could work, we have selected two pathways  as the likeliest ones 
to occur in vivo, as shown in Scheme 5 [16].  
Both the oxidative (a) and the reductive (b) activation pathways involved formation of a nitronyl 
nitroxide intermediate, a diradical. To test this hypothesis, we have carried out model experiments on 
VBN-3 demonstrating that the bisnitrone is convertible to the putative nitronyl nitroxide intermediate 
by slow oxidation with air. The nitronyl nitroxide was obtained as a purple, crystalline, and stable 
compound. This suggested that the antifungal activity against P. carinii could be greatly enhanced by 
replacing the nitrone pharmacophore with nitronyl nitroxide moieties. To achieve this, and to benefit 
from the activity enhancements expected from employing multivalent drugs,  the trisnitronyl nitroxide 
7 was synthesized, as shown in Scheme 6.  The synthesis employed the same dendrimeric core, a 






























































Scheme 5. Hypothetical pathways postulated for (a) reductive and (b) oxidative activation of VBN-3 
(from Reference [16]). 








































































multiples of the pharmacophore unit. Condensation of the trisaldehyde [31] with 2,3-dihydroxyamino-
2,3-dimethylbutane gave a colorless tris(di-N-hydroxy) intermediate which was oxidized with lead 
dioxide to afford the trisnitronyl nitroxide 7 in excellent yield. The triradical 7, obtained as a deep-blue 
colored microcrystalline material, was stable at room temperature for several months. Its structure was 
determined from a combination of spectroscopic data, and to facilitate spectral analysis of this 
paramagnetic species, it was reduced with methylhydrazine to the corresponding tris(N-hydroxy) 
derivative [32]. It had limited solubility in water, <2 mg/ml, but was very soluble in DMSO (34 
mg/ml) so it could be tested against P. carinii  in cultures at both low and high concentrations. Figure 7 
shows that the activity of the triradical 7 against P. carinii at a concentration of of 1 µg/ml is 
comparable to that of TMP/SMX, the drug in current use, and at 10 or 25 µg/ml 7 is better. These 
results confirm the hypothesis of drug action as outlined in Scheme 5, and they demonstrate that 
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